FindTrial
Sign In

Wether High Dose Intravenous Immunoglobulin could improve the survival rates of patients with acute, subacute and acute-on-chronic liver failure: a pilot trial

High Dose Intravenous Immunoglobulin for patients with liver failure

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPN-14005320
Enrollment
Unknown
Registered
2014-10-07
Start date
2010-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver failure

Interventions

IVIG Group:High Dose Intravenous Immunoglobulin and tradition
Control Group:traditional treatment

Sponsors

The Second Affiliated Hospital of Shantou University Medical College
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
11 Years to 61 Years

Inclusion criteria

Inclusion criteria: 1. patients with acute, subacute and acute-on-chronic liver failure; 2. no use of glucocorticoids or intravenous immunoglobulin, 4 weeks before the trial; 3. no serious heart, brain, lung, kidney and blood system basic diseases; 4. The patient has signed informed consent.

Exclusion criteria

Exclusion criteria: 1. chronic liver failure; 2. with serious heart, brain, lung, kidney and blood system basic diseases; 3. Selective IgA deficiency; 4. after liver transplantation; 5. pregnant or breastfeeding; 6. poor adherence.

Design outcomes

Primary

MeasureTime frame
bilirubin;Prothrombin time;Alanine aminotransferase;—

Countries

China

Contacts

Public ContactWeidong L
weidongliu206@hotmail.com+86 18929641506

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026